MIA-602, a GHRH Receptor Antagonist, Shows Promise for PTSD in Mice

Post-traumatic stress disorder (PTSD) is a debilitating mental health condition characterized by severe anxiety, depression, and cognitive dysfunction, often triggered by traumatic events. Current treatments for PTSD are often insufficient, highlighting an urgent need for novel therapeutic strategies. This study investigates the potential of targeting the growth hormone-releasing hormone (GHRH) receptor, as dysregulation of the GHRH/growth hormone (GH) axis has been implicated in stress-related disorders, addressing the knowledge gap regarding GHRH receptor antagonists as a treatment for PTSD-like emotional disorders.

The study found that MIA-602 treatment significantly improved several PTSD-like symptoms in the mouse models. Treated mice exhibited marked reductions in anxiety-like behaviors, as evidenced by improved performance in tests such as the elevated plus maze and light-dark box. Furthermore, depressive-like behaviors were substantially ameliorated, indicated by better outcomes in the forced swim test and tail suspension test. Cognitive deficits, a common feature of stress-related disorders, were also significantly reversed by MIA-602 administration. The most critical finding was that MIA-602 treatment effectively reversed the stress-induced emotional and cognitive deficits, suggesting its potential as a novel therapeutic strategy for PTSD.